Armand, P., Lee, S. T., Jurczak, W., Stevens, D., Choquet, S., Ghesquieres, H., Norasetthada, L., Pinto, A., Saydam, G., Zhou, H., Reddy, N., Yusuf, R., Ozcan, M. (2025). Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003. Blood. https://doi.org/10.1182/blood-2025-3745